June 27, 2022
Loading...
You are here:  Home  >  Banking & Finance  >  Current Article

MannKind adds to diabetes treatment portfolio with $10M acquisition

IN THIS ARTICLE

For the past few years, MannKind Corporation has been generating the majority of its revenue from its only product: Afrezza. But, by the end of May, the company could have two more products added to its portfolio, thanks in large part to MannKind’s $10 million acquisition of Zealand Pharma’s V-Go product, announced May 17. There…

Subscribe

    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.